Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia

Abstract

We hypothesized that higher Charlson comorbidity index (CCI) predicts worse 1-month mortality and overall survival (OS) in patients ≥60 years with acute myeloid leukemia (AML). In our National Cancer Database study, patients with CCI 0 were more likely to receive chemotherapy and undergo upfront hematopoietic cell transplantation. One-month mortality and OS were significantly worse with CCI 1 or ≥2, compared with CCI 0.